Cat. No.: 471 005
Amount: 50 µg
Price:
$460.00
|
|
|
| Cat. No. 471 005 |
50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze! |
| Applications | |
| Immunogen | Synthetic peptide comprising almost all of the processed mouse GLP-1(7-36)amide. (UniProt Id: P55095) |
| Reactivity |
Reacts with: mouse (P55095), rat (P06883). Other species not tested yet. |
| Specificity | The antibody recognizes GLP-1 with a preference for the amidated GLP-1(7-36)amide. It may show some cross-reactivity with the unprocessed precursor protein. |
| Remarks |
Dot blot: This application was tested with synthetic peptides only. |
| Data sheet | 471_005.pdf |
|
|
Glucagon-like peptide-1 (GLP-1) is a member of the glucagon family of hormones.
The well conserved peptide is generated by tissue-specific posttranslational processing of the proglucagon precursor, yielding the amidated GLP-1(7-36)amide or the non-amidated GLP-1(7-37) (1). In humans and mice, GLP-1 is predominantly amidated, whereas in rats both amidated and nonamidated GLP-1 is present (1,2). Both forms are biologically active and rapidly inactivated by proteolytic cleavage (1,3).
GLP-1 is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem in response to nutrient ingestion (1). Although there is some species variation, the density of L-cells increases distally along the gut, with greatest density in the ileum and colon (1,2).
GLP-1 exerts its effects via interaction with its specific G-protein-coupled receptor GLP-1R. Receptor binding stimulates insulin secretion from pancreatic beta cells.
In addition to its insulinotropic effects, GLP-1 promotes beta cell proliferation, it is involved in gastrointestinal motility, and it inhibits gastric emptying. In bone, GLP-1 inhibits bone resorption. In the brain, GLP-1 is thought to be involved in memory formation as well as in the control of appetite (1,3).
The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity and diabetes (4,5).